摘要
妇科肿瘤是威胁全世界女性生命健康的重要因素。目前复发和转移性妇科肿瘤的治疗效果仍然很差。近年来,免疫治疗、靶向治疗的飞速发展及联合治疗方案的临床突出表现,为晚期妇科肿瘤患者带来了新希望。该文初步探索了PD-1/PD-L1抑制剂联合仑伐替尼治疗恶性肿瘤的作用机制,概述了现阶段联合治疗在妇科肿瘤中的研究现况,以期为之后的临床应用提供思路和线索。
Gynecological tumors substantially threaten lives and health of women around the world.At present,the treatment of recurrent and metastatic gynecological tumors is still poor.With the rapid development of immunotherapy,targeted therapy and the evident clinical effectiveness of combination therapy in recent years,new hope has been brought to patients with advanced gynecological tumors.This article preliminarily explores the mechanism of PD-1/PD-L1 inhibitors plus lenvatinib in the treatment of malignant tumors,and summarizes the current status of combination therapy in gynecological tumors to provide ideas and direction for subsequent clinical applications.
作者
杨睿
闵婕
李俊强
苏海川
YANG Rui;MIN Jie;LI Junqiang;SU Haichuan(Department of Oncology,Tangdu Hospital,Air Force Medical University,Shaanxi Xi'an 710038,China.)
出处
《现代肿瘤医学》
CAS
2024年第14期2669-2674,共6页
Journal of Modern Oncology
基金
白求恩·精医求精-晚期实体瘤科研项目(编号:STLKY0025)。
